Genex Pharmaceutical Inc (GENX)

OTC Markets

Currency in USD

0.000

0.000(0.00%)

Closed·15/09

Fair Value

Unlock Value

Day's Range

0.000

52 wk Range

0.000

0.009

GENX Income Statement

Assess the Genex Pharma income statement, providing a detailed view of the company’s financial performance across activities. This statement outlines key financial figures such as revenue, expenses, operating income, and net income. Assess the GENX net worth.

Period Ending:

2003

31/12

2004

31/12

2005

31/12

2006

31/12

2007

31/12

Total Revenues

1.33

2.35

2.49

2.44

3.24

Total Revenues Growth

+76.3%

+6.01%

-2.13%

+32.77%

Cost Of Revenues

0.23

0.28

0.3

0.22

0.36

Gross Profit

1.1

2.07

2.19

2.22

2.87

Gross Profit Growth

+87.77%

+5.88%

+1.45%

+29.44%

Gross Profit Margin %

82.6%

87.97%

87.87%

91.08%

88.8%

Other Operating Expenses, Total

0.62

1.08

1.27

1.37

2.41

	Other Operating Expenses, Total Growth
	R&D Expenses
	Selling General & Admin Expenses
	Other Operating Expenses

-	+74.3%	+17.96%	+8.33%	+75.27%
-	-	0.09	0	0.2
0.62	1.08	1.18	1.37	2.21
-	-	-	-	-

Operating Income

0.48

0.99

0.92

0.85

0.47

Operating Income Growth

+104.94%

-7.21%

-8.03%

-44.95%

EBIT Margin %

36.32%

42.22%

36.95%

34.73%

14.4%

Net Interest Expenses

0.01

0.02

0.07

0.18

0.25

Net Interest Expenses Growth

+186.99%

+203.82%

+160.32%

+41.95%

Interest Expense, Total

Interest And Investment Income

0.01

0.02

0.07

0.18

0.25

Other Non Operating Expenses, Total

-0

0.01

EBT, Excl. Unusual Items

0.49

1.01

0.99

1.03

0.73

Gain (Loss) On Sale Of Assets

Other Unusual Items, Total

-0.04

EBT, Incl. Unusual Items

0.49

1.01

0.95

1.03

0.73

EBT, Incl. Unusual Items Growth

+105.95%

-5.91%

+7.61%

-28.49%

EBT, Incl. Unusual Items Margin

36.91%

43.12%

38.27%

42.07%

22.66%

Income Tax Expense

0.33

0.41

0.39

Net Income to Company

0.49

1.01

0.63

0.62

0.34

Minority Interest

Net Income

0.49

1.01

0.63

0.62

0.34

Net Income Growth

+105.95%

-38.32%

-0.97%

-44.66%

Net Income Margin %

36.91%

43.12%

25.09%

25.39%

10.58%

Preferred Dividend and Other Adjustments

Net Income to Common Excl. Extra Items

0.49

1.01

0.63

0.62

0.34

Basic EPS - Continuing Operations

0.03

0.06

0.04

0.03

0.02

Basic EPS - Continuing Operations Growth

+68.88%

-38.32%

-0.97%

-44.66%

Diluted EPS - Continuing Operations

0.03

0.06

0.04

0.03

0.02

Diluted EPS - Continuing Operations Growth

+68.88%

-38.32%

-0.97%

-44.66%

Basic Weighted Average Shares Outstanding

14.63

17.85

Diluted Weighted Average Shares Outstanding

14.63

17.85

Dividend Per Share

Dividend Per Share Growth

EBITDA

0.51

1.05

0.98

0.9

0.52

EBITDA Growth

+106.95%

-6.69%

-8.05%

-42.06%

EBITDA Margin %

38.09%

44.71%

39.36%

36.97%

16.13%

EBIT

0.48

0.99

0.92

0.85

0.47

* In Millions of USD (except for per share items)

FAQ

What was Genex Pharma’s revenue at year end?

At the end of the last reported fiscal year, Genex Pharma (GENX) recorded total revenue of 3.237 million USD.

How much revenue did Genex Pharma report in the most recent quarter?

In its most recent quarterly earnings report, Genex Pharma posted revenue of 0.895 million USD.

What was Genex Pharma’s net income for the year?

For the full year, Genex Pharma reported net income of 0.343 million USD.

How much net income did Genex Pharma post in the last quarter?

In the most recent quarter, Genex Pharma (GENX) posted net income of -0.073 million USD.

What was Genex Pharma’s gross profit for the year?

Gross profit for the year was reported at 2.874 million USD.

How much gross profit did Genex Pharma generate last quarter?

Genex Pharma recorded gross profit of 0.809 million USD in its latest quarterly report.

What was Genex Pharma’s annual operating income?

For the full year, Genex Pharma (GENX) reported operating income of 0.466 million USD.

What was Genex Pharma’s operating income last quarter?

Quarterly operating income was -0.080 million USD.

What was Genex Pharma’s quarterly EBITDA?

In the latest quarter, EBITDA was reported at -0.064 million USD.

What was the quarter-over-quarter change in EBITDA for Genex Pharma?

EBITDA changed by -167.611% million USD compared to the last quarter.

What is Genex Pharma’s most recent gross profit margin?

The latest reported gross profit margin for Genex Pharma (GENX) is 90.434% million USD.

What is Genex Pharma’s most recent net income margin?

Net income margin based on recent financials is -8.113% million USD.

What is Genex Pharma’s most recent EBIT margin?

Genex Pharma reported an EBIT margin of -8.888% million USD based on current figures.

How did Genex Pharma’s revenue change compared to the previous quarter?

Revenue changed by 4.122% million USD compared to the prior quarter.

What was the quarter-over-quarter change in gross profit for Genex Pharma?

In the latest quarter, gross profit changed by 2.837% million USD from the previous quarter.

S&P/TSX

35,620.03

-629.00

-1.74%

S&P/TSX 60

2,125.02

-31.76

-1.47%

US 30

51,788.50

-554.1

-1.06%

US 500

7,580.90

-139.3

-1.80%

S&P 500 VIX

19.42

+2.22

+12.91%

DAX

25,818.21

-221.47

-0.85%

Dollar Index

101.83

-0.070

-0.06%

Market Movers

Name	Last	Chg. %	Vol.
RBC	283.93	-1.49%	3.02M
TD	174.04	-2.30%	4.39M
Bank of Montreal	239.22	-2.87%	2.00M
Bank of Nova Scotia	131.05	-1.79%	3.57M
Suncor Energy	111.11	+2.26%	3.70M
Cameco	107.60	-7.74%	3.50M
Imperial Oil	193.48	+5.37%	1.94M

Name	Last	Chg. %	Vol.
Mijem Newcomm Tech	0.10	+375.00%	27.00K
Green Scientific Labs Holdings	0.06	+120.00%	15.00K
ePlay Digital	0.010	+100.00%	7.00K
Ramm Pharma	0.01	+100.00%	200.00K
Champion Electric	0.010	+100.00%	100.00K
First Growth Funds	0.03	+100.00%	70.00K
Canyon Creek	0.0250	+66.67%	7.00K

Name	Last	Chg. %	Vol.
Modern Plant Based Foods	0.070	-61.11%	2.00K
Regenera Insights	0.03	-54.55%	9.00K
Appili Therapeutics	0.0050	-50.00%	18.01K
James Bay Resources Ltd	0.005	-50.00%	35.10K
SP Strategic Acquisition	0.02	-50.00%	3.00K
Nobel Resources	0.02	-50.00%	51.00K
Playground Ventures	0.005	-50.00%	29.01K

Trending Stocks

Name	Last	Chg. %	Vol.
Air Canada	20.19	-7.68%	5.42M
TD	174.04	-2.30%	4.39M
Celestica Inc.	369.32	-6.77%	623.00K
Hut 8	82.860	-10.79%	730.78K
Telus	12.37	+2.40%	9.03M

Most Undervalued Stocks

Name	Last	Upside	Fair Value
Aaaaa Aaaa Aaaa Aaa	15.50	+58.23%	24.52
Aaaaaaaaaaaaaaaaaa	10.050	+52.85%	15.361
Aaaa Aa Aaaa	37.15	+51.77%	56.38
Aa Aa Aaaaa	8.73	+50.57%	13.15
Aa Aaaaaa	4.60	+49.71%	6.89
Aaaaaaaaaaaa	2.0700	+47.81%	3.0596
Aaaaaaaa Aaaa Aa	97.88	+46.78%	143.67

Name	Last	Upside	Fair Value
Aaaaa Aaaa Aaaa Aaa	15.50	+58.23%	24.52
Aaaaaaaaaaaaaaaaaa	10.050	+52.85%	15.361
Aaaa Aa Aaaa	37.15	+51.77%	56.38
Aa Aa Aaaaa	8.73	+50.57%	13.15
Aa Aaaaaa	4.60	+49.71%	6.89
Aaaaaaaaaaaa	2.0700	+47.81%	3.0596
Aaaaaaaa Aaaa Aa	97.88	+46.78%	143.67

See full list

Install Our AppScan QR code to install app

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.